FEATURE / US LAW & REGULATION

Retatrutide: the classification battle.

Lilly’s dispute with FDA concerns which regulatory pathway should apply. It is not a court approval of retatrutide.

Source review: 30 October 2026 · United States

What is the argument?

In Eli Lilly and Company v. Kennedy and others, Lilly challenged FDA’s refusal to classify retatrutide as a biological product. The dispute involves the regulatory definition of a protein and the statutory category of a product analogous to a protein. FDA counted at most 40 alpha amino acids; its protein definition requires more than 40. Amended court order, background and analysis ↗

What did the court decide?

The district court upheld FDA’s interpretation of its protein definition. It nevertheless set aside the agency’s reasoning on the analogous-product question and sent that issue back for reconsideration. The court did not direct FDA to classify retatrutide as a biologic. Read the amended summary-judgment order, especially pages 15–16 ↗

The December 16, 2025 final judgment vacated the designation decision and remanded for further proceedings on the analogous-products claim. Read the final judgment ↗

FDA reconsidered—and maintained its position.

FDA’s response again concluded that retatrutide is not a biological product. The letter explains the agency’s criteria for a product analogous to a protein and concludes that retatrutide does not meet them. FDA says an application would therefore need to proceed under section 505 of the Federal Food, Drug, and Cosmetic Act, rather than through a biologics licence application. This is the agency’s position on remand, not a new appellate judgment. Read FDA’s full 14-page letter, filed in the appeal ↗

Where does the appeal stand?

The Seventh Circuit’s official archive confirms oral argument on September 24, 2026. Court recording and case details ↗

Status limitation: the primary materials reviewed for this article establish the hearing and FDA’s subsequent response. We have not verified a later appellate disposition. This page does not present the appeal as finally resolved.

Why it matters

Editorial analysis: classification determines the framework under which a future application would be assessed. FDA’s letter also describes the statutory framework for follow-on biological products. That makes this a regulatory-pathway and potential future-competition story. It does not establish an availability date, future price or investment outcome. FDA’s explanation of the regulatory framework ↗

Three separate stories to keep apart

Read the primary record

1. FOUNDATIONAL CASE DOCUMENT · Court ruling: Amended order on cross-motions for summary judgment, 3 October 2025. Explains the classification dispute and the split ruling.
2. Final judgment: District court, 16 December 2025.
3. Official court archive: Seventh Circuit appeal 26-1301, oral argument of 24 September 2026.
4. Latest agency response reviewed: FDA letter of 2 October 2026, filed 8 October as appellate document 46-2.
5. Current regulatory statement: FDA’s concerns with unapproved GLP-1 drugs.

This feature concerns US law and regulatory documents. It does not determine Australian law or anyone’s individual legal position. The latest appellate disposition has not been independently verified.